Artivion (NYSE:AORT) Trading 5.9% Higher

Shares of Artivion, Inc. (NYSE:AORT) shot up 5.9% during mid-day trading on Friday . The company traded as high as $27.35 and last traded at $27.28. 123,308 shares were traded during trading, a decline of 45% from the average session volume of 225,462 shares. The stock had previously closed at $25.76.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Stifel Nicolaus lifted their price target on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. Needham & Company LLC restated a “buy” rating and set a $30.00 target price on shares of Artivion in a research report on Friday. Oppenheimer increased their price target on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, Lake Street Capital boosted their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd.

Artivion Price Performance

The company has a market cap of $1.12 billion, a price-to-earnings ratio of -111.88 and a beta of 1.74. The company has a fifty day simple moving average of $25.84 and a two-hundred day simple moving average of $23.86. The company has a quick ratio of 4.04, a current ratio of 5.63 and a debt-to-equity ratio of 1.07.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. The firm had revenue of $98.02 million for the quarter, compared to analysts’ expectations of $97.70 million. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. On average, equities research analysts anticipate that Artivion, Inc. will post 0.2 earnings per share for the current fiscal year.

Insider Transactions at Artivion

In related news, Director Anthony B. Semedo sold 9,709 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total value of $242,627.91. Following the sale, the director now owns 34,159 shares of the company’s stock, valued at approximately $853,633.41. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Artivion news, VP Matthew A. Getz sold 9,420 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $25.31, for a total transaction of $238,420.20. Following the sale, the vice president now directly owns 34,116 shares of the company’s stock, valued at approximately $863,475.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Anthony B. Semedo sold 9,709 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the transaction, the director now directly owns 34,159 shares of the company’s stock, valued at approximately $853,633.41. The disclosure for this sale can be found here. Insiders sold a total of 24,679 shares of company stock valued at $626,518 in the last ninety days. Corporate insiders own 8.10% of the company’s stock.

Institutional Trading of Artivion

Hedge funds have recently bought and sold shares of the company. nVerses Capital LLC acquired a new position in Artivion in the 2nd quarter valued at $28,000. GAMMA Investing LLC lifted its position in Artivion by 38.6% during the first quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock worth $38,000 after buying an additional 505 shares during the period. RiverPark Advisors LLC acquired a new stake in Artivion in the 2nd quarter worth about $55,000. Register Financial Advisors LLC acquired a new stake in Artivion in the 1st quarter worth about $114,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in Artivion by 291.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after buying an additional 4,154 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.